Drug class
The phrase "Drugs to Treat Neuronal Ceroid Lipofuscinosis type 2 (CLN2)" designates an indication-specific therapeutic grouping rather than a distinct pharmacologic class, primarily represented by recombinant human enzyme replacement therapy. Read more about Drugs to Treat Neuronal Ceroid Lipofuscinosis type 2 (CLN2)
2 drugs in this class 1 manufacturers
The phrase "Drugs to Treat Neuronal Ceroid Lipofuscinosis type 2 (CLN2)" designates an indication-specific therapeutic grouping rather than a distinct pharmacologic class, primarily represented by recombinant human enzyme replacement therapy.
Its principal mechanism involves administering a proenzyme replacement—specifically cerliponase alfa—directly into the cerebrospinal fluid via an intraventricular access device to restore deficient tripeptidyl peptidase 1 (TPP1) activity and clear neurotoxic lysosomal storage material.
Clinically, this therapy is indicated for pediatric patients with CLN2 disease, a severe genetic neurodegenerative form of Batten disease, to slow the decline of motor function and ambulation.
The phrase "Drugs to Treat Neuronal Ceroid Lipofuscinosis type 2 (CLN2)" designates an indication-specific therapeutic grouping rather than a distinct pharmacologic class, primarily represented by recombinant human enzyme replacement therapy Its principal mechanism involves administering a proenzyme replacement—specifically cerliponase alfa—directly into the cerebrospinal fluid via an intraventricular access device to restore deficient tripeptidyl peptidase 1 (TPP1) activity and clear neurotoxic...
The phrase "Drugs to Treat Neuronal Ceroid Lipofuscinosis type 2 (CLN2)" designates an indication-specific therapeutic grouping rather than a distinct pharmacologic class, primarily represented by recombinant human enzyme replacement therapy Its principal mechanism involves administering a proenzyme replacement—specifically cerliponase alfa—directly into the cerebrospinal fluid via an intraventricular access device to restore deficient tripeptidyl peptidase 1 (TPP1) activity and clear neurotoxic...
Its principal mechanism involves administering a proenzyme replacement—specifically cerliponase alfa—directly into the cerebrospinal fluid via an intraventricular access device to restore deficient tripeptidyl peptidase 1 (TPP1) activity and clear neurotoxic lysosomal storage material
Clinically, this therapy is indicated for pediatric patients with CLN2 disease, a severe genetic neurodegenerative form of Batten disease, to slow the decline of motor function and ambulation
Clinically, this therapy is indicated for pediatric patients with CLN2 disease, a severe genetic neurodegenerative form of Batten disease, to slow the decline of motor function and ambulation
Following a drug class requires a free Physicians Office Resource account.
